BSX stock fell after guidance for 2026 missed estimates due to slower growth in its electrophysiology segment.
Boston Scientific Corporation (NYSE:BSX) closed at $46.92 on June 16, 2026, after its 2026 outlook disappointed investors. The company reported solid Q1 2026 results but warned of revenue growth deceleration in its electrophysiology segment, a key revenue driver, suggesting market share losses to competitor Medtronic.
Shares dropped 17.2% over the past month and 53.71% over the last 52 weeks. The company’s market capitalization stands at $69.74 billion. Hedge fund holdings rose to 110 in Q4 2025 from 102 in the prior quarter, though BSX remains outside the top 40 most popular stocks among hedge funds.
The guidance miss overshadowed otherwise strong operating performance, raising concerns about competitive pressures in the medical devices sector.